Transforming Healthcare Value: Strategic Purchasing in South Africa

Strategic Purchasing Healthcare offers a pathway for South Africa’s healthcare system to deliver improved patient outcomes amid constrained resources, where traditional passive purchasing models relying on historical budgets or uncapped fee-for-service payments have fallen short in prioritising essential services or controlling expenditure. Strategic purchasing, when integrated with pay-for-performance mechanisms, can drive meaningful reform by leveraging data on population health needs and provider results to determine what services to acquire, from which providers, and at what cost. This approach ultimately supports a transition toward a value-based system that rewards measurable health improvements rather than volume alone.

Value-Driven Shifts Through Performance Contracts

The most compelling arguments centre on concrete demonstrations of cost reduction and incentive alignment, particularly through the antiretroviral medicines experience prior to 2010, when South Africa achieved more than a 50 percent decrease in drug costs via reference pricing, exchange-rate adjustments, and structured negotiations despite bearing the world’s highest HIV burden. Similarly, reimbursing general practitioners for lowering HbA1c levels among high-risk diabetic patients illustrates how pay-for-performance can encourage proactive management, patient education, and follow-up that fee-for-service arrangements typically overlook. These examples underscore the necessity of reliable data systems to monitor clinical indicators and establish evidence-based targets, revealing a clear pathway from input-focused payments to outcome-oriented contracts that limit enrolment to patients meeting defined criteria and tie manufacturer reimbursement to agreed treatment milestones.

Foundations for Data-Led Procurement

Strategic Purchasing Healthcare depends on systematic analysis of disease burden, service utilisation patterns, and provider performance data to make explicit decisions about service selection, provider choice, and contract design. Supporting elements include investment in interoperable information systems that track both utilisation and clinical outcomes, transparent prioritisation processes grounded in cost-effectiveness and equity considerations, and regulatory frameworks that enable outcome-based agreements while guarding against under-treatment risks.

Pricing Models That Reward Real-World Results

These findings highlight how performance-linked models can mitigate market-access barriers for innovative medicines, such as those posed by the Single Exit Price regime and limited private-market volumes, while protecting schemes from paying for ineffective therapies. In terms of pricing and reimbursement, the approach offers manufacturers a structured route to market through milestone-contingent payments and enables funders to align expenditures with real-world value, fostering broader industry trends toward sustainable access. Overall, scaling such strategies across public and private sectors positions South Africa to improve affordability, quality, and equity simultaneously, provided capacity exists within regulators and funders to design and refine these contracts effectively.